These findings substantiate the potential candidacy of miR‐148a‐3p, miR‐375 and miR‐27a‐3p as viable biomarkers for B‐ALL patients undergoing anti‐CD19 CAR‐T‐cell therapy. The gene discussed is CD19; the disease is precursor B-cell acute lymphoblastic leukemia.